Shots:
- Rigel to receive $125M up front and is also eligible to receive ~$835M as development, regulatory and commercial milestones as well as royalties, which will vary depending upon Rigel’s clinical development investment
- Lilly to get an exclusive WW license to Rigel’s RIPK1 inhibitors, including its R552 in all indications. The companies will co-develop R552 at specified contribution levels under which Lilly will be responsible for all costs of global commercialization & Rigel gets the right to co-commercialize R552 in the US
- Rigel will initiate P-II trials of R552 in 2021. Pursuant to the collaboration, Lilly will solely lead all clinical development of RIPK1 inhibitors in CNS diseases
Click here to read full press release/ article | Ref: PRNewswire | Image: ABC News
The post Lilly Collaborates with Rigel to Develop RIPK1 Inhibitors for Immunological and Neurodegenerative Diseases first appeared on PharmaShots.
